SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Livzon Pharmaceutical Receives NMPA Clinical Trial Approval

China's NMPA approved a clinical trial for Livzon Pharmaceutical's Tiange Dingxuan Granules.

SquawkNews Desk 1 updates Updated Oct 27, 2026, 08:51 AM UTC

Story updates

08:51:42 AM UTC
SquawkNews
Livzon erhält Studiengenehmigung für Tiange Dingxuan gegen vestibuläre Migräne Chinas Arzneimitt

Related stories

Japan's Nikkei average falls 3% M impact | EQUITY | Oct 30, 2026, 02:10 AM UTC China 5G Communications Index Falls 5.7% to Near 11-Month Low The CSI 5G Communications Index fell 5.7% in early trading, reaching its lowest level in nearly 11 months. M impact | EQUITY | Oct 30, 2026, 01:56 AM UTC Taiwan Benchmark Index Falls as Much as 3.5% to 44,726.26 Taiwan's benchmark stock index fell as much as 3.5% to 44,726.26, its lowest level since August 25. M impact | EQUITY | Oct 30, 2026, 01:56 AM UTC Beach Cities Commercial Bank Announces Third-Quarter 2026 Results M impact | EQUITY | Oct 30, 2026, 01:55 AM UTC Nikkei Index Falls 3% M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC Chongqing Gas Q3 Net Profit Falls 88.27% Year Over Year Chongqing Gas reported an 88.27% year-over-year decline in net profit for the first three quarters. M impact | EQUITY | Oct 30, 2026, 01:54 AM UTC